WO2018097750A1 - Средство для профилактики лейкоза крупного рогатого скота и способ его применения - Google Patents
Средство для профилактики лейкоза крупного рогатого скота и способ его применения Download PDFInfo
- Publication number
- WO2018097750A1 WO2018097750A1 PCT/RU2017/000404 RU2017000404W WO2018097750A1 WO 2018097750 A1 WO2018097750 A1 WO 2018097750A1 RU 2017000404 W RU2017000404 W RU 2017000404W WO 2018097750 A1 WO2018097750 A1 WO 2018097750A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- agent
- sodium chloride
- protein fraction
- leukosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the invention relates to the field of veterinary medicine and can be used for the prevention of leukemia in cattle.
- the invention extends the arsenal of means of the claimed purpose and provides lifelong resistance of animals to the leukemia virus.
- the resulting antigen-protein immunizing agent is administered to calves aged 1-3 months with Freund's complete adjuvant in a ratio of 1: 1. Immunization is carried out three times with an interval of 10-12 days.
- an amber biostimulator see RF patent JY “2420275 for CL MPKA61K31 / 194, publ. 06/10/2011 1
- polycarboxyethylene see RF patent N ° 2421 184 for CL IPC 2421 184, publ. 20.06 .201 1
- metronidazole and norsulfazole or sulfadimezin see RF patent JY "2300883 according to IPC A61K67 / 02, publ. 06/20/2007
- ligfola see RF patent JN ° 2320357 according to IPC A61K36 / 00, publ. 03/27/2008
- metronidazole and sulfonamides have a bactericidal rather than virucidal effect, which does not allow a specific effect on the leukemia virus.
- Ligfol is a hydrolyzate of natural lignin, the active principle of which are humic substances. Ligfol exhibits a stress-corrective and adaptogenic effect, injections are painful and cause long-term anxiety in animals.
- the effect of the amber biostimulator which is a mixture of succinic acid and the Dorogov stimulant antiseptic (ASD) fraction N ° 2, like any biologically active drug, has also been little studied and requires additional research.
- ASD Dorogov stimulant antiseptic
- Tuberculous toxoid is administered subcutaneously 20-30 days before vaccination with an inactivated vaccine against cattle leukemia. Tuberculous toxoid receive (see, for example, RF patent N ° 2392002 according to class IPC A61K39 / 00, publ.
- the destruction product of mycobacteria is used, and not the protein fraction isolated from it.
- the product of destruction contains proteins, and lipids, and polysaccharides. Lipids and polysaccharides increase the immunogenic load on the animal organism, change the state of homeostasis and interfere with a targeted immune response to mycobacterial proteins, which, ultimately, reduces the effectiveness of preventive measures and does not ensure the animals' lifelong resistance to disease.
- the invention is aimed at solving the problem of expanding the range of preventive drugs and the formation of new approaches to the problem of prevention of cattle leukemia, allowing to ensure lifelong resistance of animals to leukemia infection.
- the technical result achieved in this case consists in the creation of a means and method for the prevention of cattle leukemia, which allows efficiently and with minimal costs to provide a targeted immune response by enhancing cellular immunity against cattle leukemia virus by increasing the number of killer cells.
- a group of inventions is proposed, namely, a means for the prevention of cattle leukemia and a method for its use.
- the tool for the prevention of leukemia in cattle contains a water-soluble a protein fraction with a molecular weight of 18-20 kDa, isolated from the destruction products of mycobacterium tuberculosis, and characterized by the presence of peaks at a wavelength of 214 nm in the ultraviolet region of the spectrum, phosphate-buffered saline, an aqueous solution of formic aldehyde and an isotonic sodium chloride solution in the following ratio of components , wt.%:
- Mycobacterium tuberculosis 0.05-0.125% phosphate-buffered saline 9.95-24.875 aqueous solution of formic aldehyde 0.025-0.046 isotonic sodium chloride solution The rest The specified technical result in terms of the method of use of this tool is achieved in that calves 1-9 days administered once intramuscularly at a dose of 4.0-6.0 ml, an agent containing a water-soluble protein fraction with a molecular weight of 18-20 kDa, isolated from the destruction products of mycobacterium tuberculosis, and characterized by the presence of peaks at a wavelength of 214 nm ultraviolet, phosphate buffered saline, aqueous solution of formic aldehyde and isotonic sodium chloride at the following component ratio solution, wt.%:
- Mycobacterium tuberculosis 0.05-0.125% phosphate-buffered saline 9.95-24.875 aqueous solution of formic aldehyde 0.025-0.046 isotonic sodium chloride solution These signs are essential and sufficient to obtain the desired technical result.
- a mixture of formic aldehyde solution with isotonic sodium chord solution is used not as a detoxifier, but as a component that ensures the stabilization of the immune response at the level of the killer system.
- a mixture of components protein fraction with a specific molecular weight isolated from the destruction products of mycobacterium tuberculosis and a mixture of solutions formic aldehyde and sodium chloride
- killer cells inhibit the development of tumor cells (see, for example, RF patent N ° 244341 1 according to IPC A61K9 / 08, publ. 02.27.2012; RF patent L2262941 according to IPC A61K35 / 16, publ. 27.10. 2005). However, they are used solely to treat the disease.
- CD8 cytotoxic T-lymphocytes and inflammatory CD4 (Thl) T-lymphocytes are responsible for cellular immunity
- CD4 (Th2) T-helper lymphocytes and B-lymphocytes are responsible for humoral immunity.
- This invention solves the problem of enhancing effective immunity against leukemia by increasing cytotoxic lymphocytes (CD8) and inflammatory T-lymphocytes CD4 (YOU), reducing T-helper lymphocytes CD4 (Th2) and an increase in the number of the third subpopulation of T lymphocytes - ThO.
- Figure 1 shows the chromatogram of the protein fraction isolated from the destruction products of the bovine tuberculosis pathogen M. bovis (strain N.> 8).
- Cattle leukemia prophylaxis is prepared as follows.
- PPD-tuberculin for mammals is used, obtained from the M.bovis strain N ° 8 and which is a clear liquid of light brown color (see Instructions for the use of purified tuberculin (1SH) for mammals, approved by the Deputy Head of Rosselkhoznadzor 30.09 .2011).
- the liquid with the pathogen destruction products is precipitated with saline solution (for example, ammonium sulfate) and centrifuged. The supernatant is removed and the sediment is redissolved in saline buffer.
- saline solution for example, ammonium sulfate
- Dialysis is carried out, the pH of the solution is adjusted to 7.0-7.4, after which the protein concentration is determined by conventional methods, in particular, by the Lowry method.
- the choice of the pH of the solvent is explained by the value of the indicator in the cells of the body. It is well known (see, for example, http://zensHm.ru/content), that in the cells of the body the pH is about 7.0, in the extracellular fluid - 7.4.
- the molecular weight of the protein was determined using high pressure liquid chromatography (HPLC), which was carried out, in particular, on a liquid chromatograph "Stayer", using a spectrophotometric detector A214 (wavelength 214 nm).
- HPLC high pressure liquid chromatography
- a BioSep-SEC-S 2000 column of 5 ⁇ m 145A, 300x7.8 mm was used.
- 0.01 M phosphate-buffered saline, flow rate of 1 ml per minute, or 0.01 M phosphate-buffered saline with 0.025% sodium azide solution pH 6.8 and at a flow rate of 2 ml per minute were used.
- Bovine serum albumin with a molecular weight of 64 - 70 kDa, lactoferrin with a molecular weight of 75 - 80 kDa and papain with a molecular weight of 20 kDa were used as standards.
- the main proteins in the bovine tuberculosis pathogen M. bovis (strain N28) isolated from the destruction products of the causative agent had a molecular weight of 18-20 kDa (see Fig. 1).
- Table 1 presents the result of chromatography of a composition based on a protein fraction isolated from the products of the destruction of the causative agent of tuberculosis.
- the resulting protein fraction with a molecular weight of 18-20 kDa is mixed in a buffer solution that contains from 4.8 mg / ml to 5.2 mg / ml of protein (i.e., from 0.48% to 0.52%) , with isotonic sodium chloride solution 085, -0.95% concentration.
- composition of the resulting mixture will be as follows:
- Example 1 preparation for the prevention of leukemia
- the amount of protein fraction from the destruction products of the tuberculosis pathogen was 5.0 mg / ml.
- protein fractions were obtained from other batches of PPD-tuberculin.
- the amount of protein everywhere ranged from 4.8 to 5.2 mg / ml.
- the obtained protein fraction with a molecular weight of 18-20 kDa is mixed in a buffer solution containing 5 mg / ml of protein (i.e. 0.5%) with an isotonic solution of sodium chloride 085, -0.95% concentration.
- the protein fraction is mixed in phosphate-buffered saline with a mixture of solutions of formic aldehyde and sodium chloride in equal proportions - 1: 1.
- the content of the components of the drug will be as follows, wt.%:
- isotonic sodium chloride solution Similarly to the described preparation, a preparation was prepared from protein fractions with a protein content of 0.48% and 0.52%.
- Example 2 The rationale for the quantitative content of the components in the preparation.
- the claimed agent for the prevention of leukemia in cattle as well as the method of its use, provide lifelong resistance of animals to infection with leukemia by enhancing cellular immunity against leukemia virus in cattle by increasing the number of killer cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17873383.8A EP3403668A4 (en) | 2016-11-22 | 2017-06-13 | MEANS FOR PREVENTING HORN CATTLE LEUKOSIS AND METHOD OF APPLICATION |
CA3018982A CA3018982C (en) | 2016-11-22 | 2017-06-13 | Remedy for bovine leukemia prophylaxis and use thereof |
MX2019002570A MX2019002570A (es) | 2016-11-22 | 2017-06-13 | Agente para la profilaxis de la leucosis bovina y metodo para su uso. |
CN201780050553.XA CN109641040B (zh) | 2016-11-22 | 2017-06-13 | 用于预防牛白血病的药剂及其使用方法 |
BR112019003609A BR112019003609A2 (pt) | 2016-11-22 | 2017-06-13 | remédio para profilaxia de leucemia bovina e método de uso. |
AU2017363399A AU2017363399B2 (en) | 2016-11-22 | 2017-06-13 | Agent for the prophylaxis of bovine leukosis and method for the use thereof |
US15/836,943 US10434163B2 (en) | 2016-11-22 | 2017-12-11 | Remedy for bovine leukemia prophylaxis and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016145862 | 2016-11-22 | ||
RU2016145862A RU2631607C1 (ru) | 2016-11-22 | 2016-11-22 | Средство для профилактики лейкоза крупного рогатого скота и способ его применения |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/836,943 Continuation US10434163B2 (en) | 2016-11-22 | 2017-12-11 | Remedy for bovine leukemia prophylaxis and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018097750A1 true WO2018097750A1 (ru) | 2018-05-31 |
Family
ID=59931316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2017/000404 WO2018097750A1 (ru) | 2016-11-22 | 2017-06-13 | Средство для профилактики лейкоза крупного рогатого скота и способ его применения |
Country Status (9)
Country | Link |
---|---|
US (1) | US10434163B2 (ru) |
EP (1) | EP3403668A4 (ru) |
CN (1) | CN109641040B (ru) |
AU (1) | AU2017363399B2 (ru) |
BR (1) | BR112019003609A2 (ru) |
CA (1) | CA3018982C (ru) |
MX (1) | MX2019002570A (ru) |
RU (1) | RU2631607C1 (ru) |
WO (1) | WO2018097750A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048596A1 (ru) * | 2021-09-22 | 2023-03-30 | Владислав Николаевич ЛАСКАВЫЙ | Композиция для поддержания нормального состояния гомеостаза и препарат на её основе |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2005127138A (ru) * | 2005-08-29 | 2007-03-10 | Юрий Федорович Бардеев (RU) | Способ профилактики и лечения лейкоза крупного рогатого скота(варианты) |
RU2392002C2 (ru) * | 2008-04-02 | 2010-06-20 | ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова | Способ получения туберкулезного анатоксина |
RU2396978C1 (ru) * | 2009-03-05 | 2010-08-20 | Федеральное государственное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова | Способ профилактики развития лейкоза крупного рогатого скота |
RU2420275C1 (ru) * | 2009-12-16 | 2011-06-10 | Государственное научное учреждение Курский научно-исследовательский институт агропромышленного производства | Способ профилактики лейкоза крупного рогатого скота |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK79893D0 (da) * | 1993-07-02 | 1993-07-02 | Statens Seruminstitut | New vaccine |
RU2146533C1 (ru) * | 1998-08-19 | 2000-03-20 | Ласкавый Владислав Николаевич | Способ профилактики туберкулеза молодняка крупного рогатого скота |
EP1527159A4 (en) * | 2002-06-21 | 2006-10-04 | Univ Newcastle Res Ass | PROBIOTIC PROPIONIBACTERIUM JENSENII 702 |
US8287879B2 (en) * | 2003-10-16 | 2012-10-16 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
RU2390559C1 (ru) * | 2008-10-22 | 2010-05-27 | Государственное образовательное учреждение высшего профессионального образования Казанский государственный медицинский университет | Способ получения антигена из micobacterium tuberculosis |
RU2648842C2 (ru) * | 2011-01-04 | 2018-03-28 | Арчивель Фарма, С.Л. | Липосомный препарат, предназначенный для лечения или предупреждения туберкулеза |
AU2014312135B2 (en) * | 2013-08-30 | 2017-09-07 | Longhorn Vaccines And Diagnostics, Llc | Enhancing immunity to tuberculosis |
RU2558924C1 (ru) * | 2014-07-15 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации" | Способ профилактики лейкоза молодняка крупного рогатого скота |
-
2016
- 2016-11-22 RU RU2016145862A patent/RU2631607C1/ru active
-
2017
- 2017-06-13 BR BR112019003609A patent/BR112019003609A2/pt unknown
- 2017-06-13 MX MX2019002570A patent/MX2019002570A/es unknown
- 2017-06-13 EP EP17873383.8A patent/EP3403668A4/en not_active Withdrawn
- 2017-06-13 CA CA3018982A patent/CA3018982C/en active Active
- 2017-06-13 WO PCT/RU2017/000404 patent/WO2018097750A1/ru active Application Filing
- 2017-06-13 AU AU2017363399A patent/AU2017363399B2/en not_active Ceased
- 2017-06-13 CN CN201780050553.XA patent/CN109641040B/zh active Active
- 2017-12-11 US US15/836,943 patent/US10434163B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2005127138A (ru) * | 2005-08-29 | 2007-03-10 | Юрий Федорович Бардеев (RU) | Способ профилактики и лечения лейкоза крупного рогатого скота(варианты) |
RU2392002C2 (ru) * | 2008-04-02 | 2010-06-20 | ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова | Способ получения туберкулезного анатоксина |
RU2396978C1 (ru) * | 2009-03-05 | 2010-08-20 | Федеральное государственное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова | Способ профилактики развития лейкоза крупного рогатого скота |
RU2420275C1 (ru) * | 2009-12-16 | 2011-06-10 | Государственное научное учреждение Курский научно-исследовательский институт агропромышленного производства | Способ профилактики лейкоза крупного рогатого скота |
Non-Patent Citations (1)
Title |
---|
See also references of EP3403668A4 * |
Also Published As
Publication number | Publication date |
---|---|
US10434163B2 (en) | 2019-10-08 |
CN109641040B (zh) | 2023-02-28 |
EP3403668A1 (en) | 2018-11-21 |
BR112019003609A2 (pt) | 2019-07-09 |
CA3018982C (en) | 2022-09-13 |
RU2631607C1 (ru) | 2017-09-25 |
EP3403668A4 (en) | 2019-11-27 |
CN109641040A (zh) | 2019-04-16 |
MX2019002570A (es) | 2019-07-01 |
US20180169207A1 (en) | 2018-06-21 |
AU2017363399B2 (en) | 2019-09-26 |
AU2017363399A1 (en) | 2019-02-14 |
CA3018982A1 (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boone et al. | Virus‐augmented tumor transplantation antigens: Evidence for a helper antigen mechanism | |
JPH07504683A (ja) | Gm−csfのワクチンアジュバントとしての利用 | |
James et al. | The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis. | |
Hirsch et al. | Effects of anti-thymocyte serum on Rauscher virus infection of mice | |
RU2631607C1 (ru) | Средство для профилактики лейкоза крупного рогатого скота и способ его применения | |
WO2024066288A1 (zh) | 一种疫苗佐剂、疫苗组合物及其应用 | |
JPS6338971B2 (ru) | ||
JPS6236501B2 (ru) | ||
RU2396978C1 (ru) | Способ профилактики развития лейкоза крупного рогатого скота | |
RU2676266C2 (ru) | Адъювант для противовирусных вакцин | |
CA2136870C (fr) | Complexe immunomodulateur anti-sida | |
WO2019202285A1 (en) | Pharmaceutical compositions and associated kits and uses | |
Zhang et al. | Exosome co-delivery of a STING agonist augments immunogenicity elicited by CVB3 VP1 vaccine via promoting antigen cross-presentation of CD8+ DCs | |
WO2024040979A1 (zh) | 一种人参酸性多糖疫苗佐剂、疫苗组合物及其应用 | |
HRP20050763A2 (en) | Ganglioside based vaccine compositions for subcutaneous administration | |
Savina et al. | The effect of synthetic adjuvant on the formation of the immune response | |
AU2012229234A1 (en) | Vaccine formulation of mannose coated peptide particles | |
JPS6236500B2 (ru) | ||
CN112138151B (zh) | 一种口蹄疫疫苗组合物及其制备方法和应用 | |
CN116115746A (zh) | 含有木鳖子总皂苷和铝盐的疫苗佐剂及其疫苗组合物 | |
Seiler et al. | BCG versus VCN: The antigenicity and the adjuvant effect of both compounds | |
RU2380405C2 (ru) | Способ получения рекомбинантного альфа 16-интерферона человека и фармацевтическая композиция для лечения вирусных заболеваний на основе рекомбинантного альфа 16-интерферона человека | |
CA1036494A (en) | Vaccine for the prevention and treatment of vascular conditions | |
SCHMIDTKE et al. | Experimental models of tumor immunotherapy | |
Hernandez-Franco et al. | EFFECTS EFFECTIVE AND SAFE STIMULATION OF HUMORAL AND CELL-MEDIATED IMMUNITY BY INTRADERMAL IMMUNIZATION WITH A CYCLIC-DINUCLEOTIDE/NANOPARTICLE COMBINATION ADJUVANT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2017873383 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017873383 Country of ref document: EP Effective date: 20180816 |
|
ENP | Entry into the national phase |
Ref document number: 3018982 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017363399 Country of ref document: AU Date of ref document: 20170613 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019003609 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112019003609 Country of ref document: BR Free format text: APRESENTE A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE RU 2016145862; OU DECLARACAO DE QUE OS DADOS DO PEDIDO INTERNACIONAL ESTAO FIELMENTE CONTIDOS NA PRIORIDADE REIVINDICADA, CONTENDO TODOS OS DADOS IDENTIFICADORES DESTA (TITULARES, NUMERO DE REGISTRO, DATA E TITULO), CONFORME O PARAGRAFO UNICO DO ART. 25 DA RESOLUCAO 77/2013. |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112019003609 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190222 |